I agree with Ohm that it will be difficult for some BP to buy us but not completely impossible. If after the BLA is accepted by the FDA and before approval this will be the only time BP can strike. And if you are convinced of the science of LL I think a majority of some BP companys shareholders will be also, for a platform drug.

But if They don't strike then, and we get approval for HIV all bets are off.
As to the other indications the only indications that might get approval next year Q1 is one for covid, may be also LH, and those would only be EUAs. As for HIV the BLA has to be accepted by the FDA and a PDUFA date will then be set within 6 Months.

All the the rest still needs a phase three trial, getting any approval before then is very rare. And a P3 for either cancer trial or Nash will run 2-3 Years total before approval. 6 months to set up a phase 3, 12-18 months for a trial, plus with cancer they have to look at survival which adds months, then BLA submission and 6-10months for approval.

But if we make a decent amount off a Covid application and HIV starts producing everything falls into place. Approval after approval after.........
The Platform drug that keeps on giving

PS. With each new approval, patents can be extended for each different disease